Drug Profile
Research programme: protein kinase inhibitors - PKU Healthcare
Latest Information Update: 11 Sep 2023
Price :
$50
*
At a glance
- Originator PKU Healthcare
- Class Antineoplastics
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 11 Sep 2023 Discontinued - Preclinical for Cancer in China (unspecified route) (PKU Healthcare website, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in China
- 20 Jul 2016 Preclinical trials in Cancer in China (unspecified route)